Receipt of live, attenuated vaccine within 30 days prior to the first dose of investigational treatment; Note: patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of investigational treatmentXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab \r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before randomization or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXReceipt of a live vaccine within 30 days prior to registration for protocol therapyXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1Xx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXPatients must not have received a live attenuated vaccination within 28 days prior to sub-study registrationXx_NEWLINE_xXPatients are ineligible if administration of a live, attenuated vaccine within 4 weeks before randomizationXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 28 days prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab; Note: influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 28 days prior to randomization or at any time during the studyXx_NEWLINE_xXPatients must not have received of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXPatient must not receive live, attenuated influenza vaccine within 4 weeks prior to registration or at any time during the study and until 5 months after the last dose of atezolizumabXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXReceipt of a live, attenuated vaccine within 4 weeks prior to randomization, during treatment, or within 5 months following the last dose of atezolizumab/placeboXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xX17. Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving TAB001;Xx_NEWLINE_xXReceived a live-virus vaccination within 30 days of planned treatment start.Xx_NEWLINE_xXAdministration of live vaccine within 4 weeks prior to study entryXx_NEWLINE_xXVaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowedXx_NEWLINE_xXTreatment with a live, attenuated vaccine within 4 weeks before initiation of study treatment, or anticipation of need for such a vaccine during the course of the studyXx_NEWLINE_xXHave received a live-virus vaccine within 30 days prior to planned treatment start.Xx_NEWLINE_xXLive vaccine within 30 days prior to day 1 of protocol therapy (e.g. measles, mumps, rubella, varicella, yellow fever, rabies, Bacillus Calmette–Guerin [BCG], oral polio vaccine, and oral typhoid)Xx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving study therapy.Xx_NEWLINE_xXReceived live-virus vaccination within 30 days (seasonal flu vaccine allowed if non-live virus)Xx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXReceipt of live vaccine within 28 days of planned first dose of TVECXx_NEWLINE_xXSAFETY RUN-IN: Has received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXRANDOMIZED PHASE II CLINICAL TRIAL: Has received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of study drug; seasonal influenza vaccination is permitted excluding the nasal spray formulationXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXReceipt of a live virus vaccine within 28 days prior to Day 1 of Cycle 1Xx_NEWLINE_xXReceived a live vaccine within 30 days of the first dose of study medicationXx_NEWLINE_xXAdministration of a live vaccine within 30 days prior to first dose of study drugXx_NEWLINE_xXReceived a live vaccine within 30 days prior to first dose of study drugXx_NEWLINE_xXHas received a live vaccine within 28 days of planned start of study therapyXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial drug.Xx_NEWLINE_xXHas received a live vaccine within 28 days of planned start of study therapyXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of study therapyXx_NEWLINE_xXHas received a live-virus vaccine within 30 days prior to first dose of study medication.Xx_NEWLINE_xXReceipt of a live vaccine within 30 days of start of study treatmentXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of study therapyXx_NEWLINE_xXReceipt of live attenuated vaccines (including, but not limited to: intranasal influenza vaccine [FluMist], measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guerin [BCG], and typhoid vaccine) within 30 days before the first dose of study treatmentXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 28 days prior to randomization or anticipation that such vaccine will be required during the study. Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist) within 28 days prior to randomization, during treatment or within 5 months following the last dose of atezolizumab/placebo.Xx_NEWLINE_xXPatients who have received a live vaccine within 30 days of the planned start of study therapyXx_NEWLINE_xXAdministration of a live attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the studyXx_NEWLINE_xXMust not have received a live vaccine within 30 days of planned start of the study therapyXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXHave received a live vaccine within 30 days before the first dose of study treatment.Xx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumabXx_NEWLINE_xXVaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowedXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXHas received a live vaccine within 30 days prior to first dose of study drug.Xx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1Xx_NEWLINE_xXTreatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the studyXx_NEWLINE_xXReceived a vaccine within 7 days of first doseXx_NEWLINE_xXPatients should not receive immunization with attenuated live vaccine within one week of study entry or during study periodXx_NEWLINE_xXReceived live vaccine within 30 days of planned start of study medicationXx_NEWLINE_xXReceived a live vaccine within 30 days of planned start of study medicationXx_NEWLINE_xXHas received a live vaccine within 28 days of planned start of study therapyXx_NEWLINE_xXTreatment with therapeutic oral or intravenous (IV) antibiotics; or with a live, attenuated vaccine; or systemic immunosuppressive medicationXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks prior to Cycle 1 Day 1 or at any time during the study and for at least 5 months after the last dose of study drugXx_NEWLINE_xXHas received a live-virus vaccination within 30 days of planned treatment start.Xx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumabXx_NEWLINE_xXReceived a live vaccine within 30 days of the first dose of treatment.Xx_NEWLINE_xXReceipt of a live virus vaccine within 28 days prior to Day 1 of Cycle 1Xx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live attenuated vaccine will be required during the study; inactivated vaccines (such as hepatitis A or polio vaccines) are permitted during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must no receive live attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 and for at least 12 weeks after the last doseXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study. Influenza vaccination should be given during influenza season only. Participants must not receive live, attenuated influenza vaccine within 4 weeks prior to Cycle 1, Day 1, at any time during the study or 5 months after the last dose of atezolizumabXx_NEWLINE_xXReceived a live vaccine =< 30 days prior to registrationXx_NEWLINE_xXReceipt of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the studyXx_NEWLINE_xXPatients should not be vaccinated with live attenuated vaccines within 1 month of starting tremelimumab and durvalumab treatment; subjects, if enrolled, should not receive live vaccine during the study and 180 days after the last dose of both drugsXx_NEWLINE_xXPatients should not receive immunization with attenuated live vaccine within one week of study entry or during study periodXx_NEWLINE_xXImmunization with any attenuated live vaccine within 1 week prior to initiating protocol-indicated treatment.Xx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study. Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study.Xx_NEWLINE_xXVaccinations with a live vaccine within 28 days prior to start of treatment or need for live vaccine at any time during study treatment.Xx_NEWLINE_xXReceipt of live attenuated vaccine within 30 days prior to the first dose of study drug. Note: Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and up to 30 days after the last dose of study treatment.Xx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine ? 30 days prior to study registrationXx_NEWLINE_xXSubjects vaccinated with a live (attenuated) vaccine (e.g., FluMist) or a killed (inactivated)/subunit vaccine (e.g., PNEUMOVAX, Fluzone) within 28 days or 14 days, respectively, of the first planned dose of ETBX vaccineXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXVaccine administration of live vaccines within 28 days of enrollmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the initiation of lymphodepletion.Xx_NEWLINE_xXVaccination with a live vaccine < 28 days prior to the start of treatmentXx_NEWLINE_xXLive attenuated vaccinations 14 days prior to treatmentXx_NEWLINE_xXReceipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Subjects, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.Xx_NEWLINE_xXHas received a live vaccine within 28 days prior to registrationXx_NEWLINE_xXHas received a live attenuated vaccine within 28 days before the first dose of study drugXx_NEWLINE_xXReceived live or attenuated vaccination within 28 days prior to the start of NMA-LDXx_NEWLINE_xXLive vaccine within 4 weeks of the first dose of pembrolizumab and while on trial is prohibitedXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of study drugXx_NEWLINE_xXReceipt of attenuated vaccine within 2 weeks prior to starting study treatment.Xx_NEWLINE_xXVaccinated with live, attenuated vaccine within 4 weeks or as recommended by the product manufacturer prior to the first dose, during treatment, or within 100 days of the last dose of JNJ-64407564Xx_NEWLINE_xXLive vaccination within the last 30 daysXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of the trial drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette - Guérin (BCG), and typhoid vaccine.Xx_NEWLINE_xXGENERAL: Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study.Xx_NEWLINE_xXReceived live vaccine within 28 days prior to enrollmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of study treatment.Xx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only; patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXLive vaccine ? 4 weeks prior to enrollmentXx_NEWLINE_xXAdministration of a live vaccine within 4 weeks prior to study entryXx_NEWLINE_xXReceived any live vaccine within the last 30 daysXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving study treatmentXx_NEWLINE_xXReceipt of a live, attenuated vaccine within 4 weeks prior to randomisation or anticipation that a live, attenuated vaccine will be required during atezolizumab/placebo treatment or within 5 months after the last dose of atezolizumab/placeboXx_NEWLINE_xXPatients who have received a live vaccine within 30 days prior initiation of the systemic regimenXx_NEWLINE_xXTreatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during treatment with avelumab or within 5 months after the last dose of avelumab\r\n* Attenuated live vaccines include but are not limited to:\r\n** Tuberculosis (Bacillus Calmette-Guerin [BCG])\r\n** Oral polio vaccine\r\n** Measles, mumps, rubella, alone or as part of measles/mumps/rubella vaccine (MMR)\r\n** Rotavirus\r\n** Yellow fever\r\n** Typhoid\r\n** Rabies vaccine should be utilized as recommended by an infectious disease specialist\r\n** Nasal flu vaccineXx_NEWLINE_xXReceived a live vaccine within 4 weeks prior to the start of study drugXx_NEWLINE_xXPatients who have received a live vaccine within 30 days prior initiation of the systemic regimenXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before start of study treatment or anticipation that such a live, attenuated vaccine will be required during the study.\r\n* Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to start of study treatment or at any time during the study.Xx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of trial therapy.Xx_NEWLINE_xXReceipt of a live vaccine =< 30 days prior to registrationXx_NEWLINE_xXReceipt of live attenuated vaccine within 30 days before the first dose of study treatmentXx_NEWLINE_xXThe participant has received a live vaccine within 28 days prior to the first dose of trial treatment and while participating in the trial; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, Bacillus Calmette–Guerin (BCG), and typhoid vaccine; the use of the inactivated seasonal influenza vaccine (Fluzone) is allowedXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live attenuated vaccine will be required during the studyXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to the first dose of IP; Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IPXx_NEWLINE_xXHas received a live vaccine within 30 days of first study procedure (apheresis)Xx_NEWLINE_xXHas received a live-virus vaccination within 30 days of planned treatment startXx_NEWLINE_xXPatients who have received live, attenuated vaccine within 28 days prior to the first dose of PD-1 inhibitor.Xx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to the first dose of Vicinium or durvalumabXx_NEWLINE_xXReceipt of live attenuated vaccine within 28 calendar days prior to the first study treatment is NOT permittedXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of study drugXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to first anticipated dose of nivolumabXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumabXx_NEWLINE_xXReceived a live vaccine within 30 days prior to start of study treatmentXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment with atezolizumab or anticipation that such a live, attenuated vaccine will be required during the study; influenza vaccination should be given during influenza season only (approximately October to May in the Northern Hemisphere); patients must agree not to receive live attenuated influenza vaccine (e.g., FluMist) within 28 days prior to study treatment, during treatment, or within 90 days following the last dose of atezolizumabXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab.Xx_NEWLINE_xXPatients must agree not to receive any live, attenuated influenza vaccine (e.g., FluMist) within 28 days prior to receiving study treatment, during treatment or within 5 months following the last dose of atezolizumabXx_NEWLINE_xXReceipt of live attenuated vaccination within 6 months prior to study entry or within 30 days of receiving durvalumabXx_NEWLINE_xXVaccination with a live vaccine a minimum of 28 days prior to the start of treatmentXx_NEWLINE_xXReceived a live vaccine =< 30 days prior to registrationXx_NEWLINE_xXAdministration of a live vaccine within 6 weeks of first dose of study drugXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study a) Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior the first dose of durvalumab (NOTE: If a vaccine is part of the treatment regimen for the indication under study, the vaccine is permitted)Xx_NEWLINE_xXReceipt of live attenuated vaccine within 30 days prior to study entry; enrolled patients should not receive live vaccine during the study and 30 days after the last dose of durvalumabXx_NEWLINE_xXHas received a live vaccine within 30 days prior to first doseXx_NEWLINE_xXReceipt of a live vaccine within 30 days of receipt of study therapyXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumabXx_NEWLINE_xXPatients who received a live, attenuated vaccine =< 30 days before study treatment or are anticipated to require such a live attenuated vaccine are not eligible\r\n* NOTE: Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) =< 30 days prior to study registration or at any time during the studyXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumabXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle1 day 1 or anticipation that such a live attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); subjects must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1 day 1 or at any time during the studyXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumabXx_NEWLINE_xXHave received any live vaccination within 28 days of first dose of study drugXx_NEWLINE_xXAny live, attenuated vaccine within 28 days prior to the first day of treatment or during study treatment, or unwillingness to avoid live, attenuated vaccines within 90 days following the last dose of atezolizumabXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXPatients who have received a live vaccine within 30 days prior to the first dose of pembrolizumabXx_NEWLINE_xXReceipt of a live virus vaccine =< 2 months prior to registrationXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab, or active infectionXx_NEWLINE_xXVaccination with a live vaccine a minimum of 28 days prior to the start of treatmentXx_NEWLINE_xXAny live vaccine or non-oncology vaccine therapy used for prevention of infectious diseases (for up to one month prior to or after any dose of ipilimumab).Xx_NEWLINE_xXReceived live vaccine within 28 days prior to enrollmentXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumabXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXVaccinated with live, attenuated vaccine(s) within 28 days prior to first dose of study drugXx_NEWLINE_xXReceived a live vaccine =< 30 days prior to registrationXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab OR tremelimumab.Xx_NEWLINE_xXAdministration of a live, attenuated vaccine =< 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) =< 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXAdministration of a live vaccine within 4 weeks prior to start of protocol therapyXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks for first study treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to registrationXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab (MEDI4736) or tremelimumabXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXVaccinated with live, attenuated vaccine within 4 weeks of first dose of study drugXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before enrollment or anticipation that such a live attenuated vaccine will be required during the study or for 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March)\r\n* Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to enrollment, at any time during the study, or for 5 months after the last dose of atezolizumabXx_NEWLINE_xXLive, attenuated vaccine within 30 days prior to the first dose of protocol therapyXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumabXx_NEWLINE_xXHas received a live attenuated vaccine within 28 days before the first dose of study drugXx_NEWLINE_xXSubjects must not have received a live vaccine within 30 days prior to the first dose of study medicationXx_NEWLINE_xXHave received a live vaccine within 30 days prior to the first dose of trial treatment.Xx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab (e.g. live attenuated influenza vaccine [LAIV], measles/mumps/rubella vaccine [MMR], variola virus vaccine [VAR], zoster, yellow fever, etc.)Xx_NEWLINE_xXReceived a live vaccine within 30 days of first protocol treatmentXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumabXx_NEWLINE_xXPatients who have received a live attenuated vaccine =< 30 days prior to registration are not eligibleXx_NEWLINE_xXHas received or will receive a live vaccine within 30 days prior to the first administration of study medication; seasonal flu vaccines that do not contain live virus are permittedXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumabXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumabXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXReceipt of live, attenuated vaccine within 28 days prior to the first dose of investigational products (NOTE: Subjects, if enrolled, should not receive live vaccine during the study and 180 days after the last dose of investigational products)Xx_NEWLINE_xXReceipt of live, attenuated vaccine within 28 days prior to the first dose of durvalumab and tremelimumab (NOTE: subjects, if enrolled, should not receive live vaccine during the study and for 180 days after the last dose of both drugs)Xx_NEWLINE_xXLive attenuated vaccinations within 14 days prior to treatmentXx_NEWLINE_xXReceipt of a live/attenuated vaccine within 6 weeks prior to the screening visit.Xx_NEWLINE_xXPatients who received a live, attenuated vaccine =< 28 days before study registration or are anticipated to require such a live attenuated vaccine are not eligible; NOTE: Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) =< 28 days prior to study registration or at any time during the studyXx_NEWLINE_xXLive attenuated vaccinations 14 days prior to treatmentXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry (or due to receive one within 30 days of receiving either MEDI4736 or tremelimumab)Xx_NEWLINE_xXHave received a live vaccine within 30 days before the first dose of study treatment.Xx_NEWLINE_xXReceived a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXReceipt of a live vaccine within 30 days of study entryXx_NEWLINE_xXReceived live vaccine =< 30 days prior to registrationXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumabXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXReceipt of live, attenuated vaccine within 28 days prior to the first dose of durvalumab (Note: enrolled patients should not receive live vaccine during the study and for 180 days after the last dose of durvalumab)Xx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumabXx_NEWLINE_xXHas received a live vaccine 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live attenuated vaccine within 30 days prior to enrolling in the study.Xx_NEWLINE_xXReceipt of a live, attenuated vaccine within 28 days prior to the first dose of MEDI4736 and tremelimumab (NOTE: subjects, if enrolled, should not receive live vaccine during the study or for 180 days after the last dose of both drugs)Xx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 6 months of receiving MEDI4736 or MEDI + tremelimumabXx_NEWLINE_xXReceived a live virus vaccine within 30 days of planned start of therapyXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapy.Xx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to registration; NOTE: patients should also not receive such vaccination within 30 days of receiving durvalumab or tremelimumabXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study; influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXReceipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IP.Xx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXReceived a live virus vaccine within 30 days of planned start of study treatmentXx_NEWLINE_xXReceipt of live or live attenuated vaccine within 12 weeks prior to enrollmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXPHASE I STUDY ELIGIBILITY CRITERIA:\r\nReceipt of live attenuated vaccination within 30 days before the first dose of MEDI4736Xx_NEWLINE_xXPHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nReceipt of live attenuated vaccination within 30 days before the first dose of MEDI4736Xx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXSubject has received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHave received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks prior to enrollment or anticipation that such a live attenuated vaccine will be required during the studyXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of study drugXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXReceipt of live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXVaccination with a live vaccine within 28 days of the initiation of treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXLive attenuated vaccination administered within 30 days prior to randomization.Xx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to receiving MEDI4736Xx_NEWLINE_xXReceived a live vaccine within 30 days prior to first dose of study drugXx_NEWLINE_xXPatient has received a live vaccine within 4 weeks prior to the first dose of treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXTreatment with a live virus vaccine during the 3 months prior to baseline visit; no live vaccines will be allowed throughout the course of this studyXx_NEWLINE_xXAny non-oncology live vaccine therapy used for prevention of infectious diseases (for up to one month prior to or after any dose of ipilimumab).Xx_NEWLINE_xXAdministration of a live vaccine within 6 weeks of first dose of study drugXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapy.Xx_NEWLINE_xXHave received any live vaccine within 14 days prior to first study drug administration.Xx_NEWLINE_xXReceived a live attenuated vaccine within 28 days of first study dose, unable to take oral medicationsXx_NEWLINE_xXHistory of receiving a live vaccine 30 days prior to study treatment.Xx_NEWLINE_xXReceipt of any live vaccine within 4 weeks.Xx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXReceipt of live attenuated vaccine within 30 days prior to the first dose of investigational treatment; Note: patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of investigational treatmentXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days after receiving the last dose of durvalumab.Xx_NEWLINE_xXHas received a live-virus vaccination within 30 days of planned treatment start.Xx_NEWLINE_xXPatients who have had a live, attenuated vaccine within 4 weeks before initiation of study treatment or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab.\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks before initiation of study treatment or at any time during the studyXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such vaccine will be required during the study\r\n* Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to randomization, during treatment or within 5 months following the last dose of atezolizumab/placeboXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of study treatmentXx_NEWLINE_xXReceived a live vaccine within 30 days prior to the first dose of study treatment.Xx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study. (Influenza vaccination should be given during influenza season only [approximately October to March]. Patients must not receive live, attenuated influenza vaccine [e.g., FluMist] within 4 weeks prior to cycle 1, day 1 or at any time during the study.)Xx_NEWLINE_xXReceived live vaccine within 28 days prior to enrollmentXx_NEWLINE_xXReceipt of live attenuated vaccine within 30 days prior to the first dose of study drugs; Note: Patients, if enrolled, should not receive live vaccine whilst receiving treatment with study drugs and up to 90 days after the last dose of study drugsXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatment.Xx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumabXx_NEWLINE_xXReceipt of live, attenuated vaccine within 30 days prior to study entry or the first dose of MEDI0457.\r\n* Note: patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IP.Xx_NEWLINE_xXPatient has received a live vaccine within 30 days prior to first doseXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 30 days before week 1, day 1 or anticipation that such a live attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only; patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to week 1, day 1 or at any time during the studyXx_NEWLINE_xXLive, attenuated vaccine within 30 days prior to day 1 of protocol therapyXx_NEWLINE_xXIs known to have received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumabXx_NEWLINE_xXLive vaccine within 30 days prior to treatment initiation.Xx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days prior to study entryXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior the first dose of durvalumabXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks of Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the studyXx_NEWLINE_xXPatients who receive a live attenuated vaccine =< 28 days prior to registration are not eligibleXx_NEWLINE_xXPatients are excluded for receiving any non-oncology vaccine therapy used for prevention of infectious diseases for up to four weeks (28 days) prior to or after any dose of ipilimumab; NOTE: Patients are permitted to receive the seasonal influenza vaccine; if seasonal influenza vaccine is considered, killed vaccines should be recommendedXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to step 1 registrationXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study and until 5 months after the last dose of atezolizumabXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks of the start of treatment or anticipation that such a live, attenuated vaccine will be required during the studyXx_NEWLINE_xXPatients who have received a live vaccine within 30 days prior to the radiation therapyXx_NEWLINE_xXImmunization with a live/attenuated vaccine within 30 days of enrollmentXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumabXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first protocol treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXNo prior vaccine therapyXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXReceived a live vaccine =< 30 days of planned start of study therapyXx_NEWLINE_xXPatients who have received any non-oncology live vaccine therapy used for prevention of infectious diseases (for up to one month prior to or after any dose of ipilimumab/vaccine)Xx_NEWLINE_xXReceived any live vaccine =< 30 days prior to registrationXx_NEWLINE_xXReceived a live vaccine within 1 week prior to the first dose of study treatmentXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXHas received a live vaccine within 30 days prior to transplant admissionXx_NEWLINE_xXReceived a live vaccine within 30 days of planned start of study medicationXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study drug (Cycle 1, Day 1).Xx_NEWLINE_xXHas received a live vaccine within 30 days of the first dose of study therapyXx_NEWLINE_xXHas received a live vaccine within 30 days prior to first dose of study drug.Xx_NEWLINE_xXReceived a live vaccine within 30 days prior to the first dose of study medicationXx_NEWLINE_xXLive vaccine use within 30 days of first dose of study medication.Xx_NEWLINE_xXhave received any recent (within 28 days prior to randomization) live virus vaccinationXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before first dosing or during the study.Xx_NEWLINE_xXHas received live, attenuated vaccine within 30 days prior to Study Day 1Xx_NEWLINE_xXPatient who requires live vaccine administrationXx_NEWLINE_xXThe participant has received a live vaccine within 28 days prior to registration; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine; the use of the inactivated seasonal influenza vaccine is allowedXx_NEWLINE_xXPatients must not have received immunization with an attenuated live vaccine within seven days prior to registration nor have plans to receive such vaccination while on protocol treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapy.Xx_NEWLINE_xXHas received a live virus vaccine within 30 days of allocation.Xx_NEWLINE_xXPatients must not have received a live attenuated vaccination within 28 days prior to sub-study registrationXx_NEWLINE_xXPatients must not have received a live attenuated vaccination within 28 days prior to RE-TREATMENT registrationXx_NEWLINE_xXSubject has received a live, attenuated vaccine within 28 days prior to Cycle 1 Day 1;Xx_NEWLINE_xXReceipt of live, attenuated vaccine within 30 days prior to the first dose of durvalumabXx_NEWLINE_xXReceipt of live, attenuated vaccine within 28 days prior to the first dose of investigational productXx_NEWLINE_xXReceived a live-virus vaccination within 30 days of planned start of study medication.Xx_NEWLINE_xXReceipt of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the studyXx_NEWLINE_xXHas received a live virus vaccine within 30 days of randomization.Xx_NEWLINE_xXReceipt of live, attenuated vaccine within 30 days prior to the first dose of IP (NOTE: Subjects, if enrolled, should not receive live vaccine during the study and for 30 days after the last dose of durvalumab).Xx_NEWLINE_xXReceived live vaccine within 28 days prior to enrollmentXx_NEWLINE_xXHas received live, attenuated vaccine within 30 days prior to Study Day 1Xx_NEWLINE_xXLive vaccine within 30 days of planned start of study drugXx_NEWLINE_xXTreatment with a live vaccine or a live, attenuated vaccine (e.g., nasal spray of live attenuated influenza vaccine or FluMist®) within 4 weeks prior to initiation of study drug or anticipation that such treatment will be required during the study or within 5 months after the final dose of study drugXx_NEWLINE_xXReceived a live virus vaccine within 30 days of planned study startXx_NEWLINE_xXNon oncology vaccine therapies for prevention of infectious disease (for example, seasonal flu vaccine, human papilloma virus vaccine) within 4 weeks of trial drug administration. Vaccination while on trial is also prohibited except for administration of inactivated vaccines (for example, inactivated seasonal influenza vaccine)Xx_NEWLINE_xXHas taken any prohibited medications that are listed in the protocol within 14 days of the first dose of study treatment. Subject has received or will receive a live vaccine within 30 days before the first administration of study treatmentXx_NEWLINE_xXVaccination with a live vaccine within 28 days prior to treatmentXx_NEWLINE_xXHas received a live virus vaccine within 30 days of planned start of trial treatmentXx_NEWLINE_xXSubjects who have received any non-oncology live vaccine therapy used for prevention of infectious diseases for up to 28 days prior to or after the initiation of treatment in this studyXx_NEWLINE_xXHas received a live-virus vaccination within 30 days of planned treatment startXx_NEWLINE_xXReceipt of a live vaccine within 30 days before the first dose of study treatment.Xx_NEWLINE_xXTreatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study, or up to 5 months following the anticipated last dose of atezolizumabXx_NEWLINE_xXSubject has received a live virus vaccine within the previous 8 weeks.Xx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks prior to enrollmentXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study drug (Cycle 1, Day 1)Xx_NEWLINE_xXHas received a live vaccine within 30 days of the planned first dose of the studyXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to first dose of MEDI4736Xx_NEWLINE_xXAny non-oncology live or attenuated vaccine therapy used for prevention of infectious diseases within 30 days prior to the first dose of tremelimumab; if patients is enrolled, patient should not receive live vaccine during the study and 180 days after the last dose of tremelimumabXx_NEWLINE_xXVaccination with a live virus vaccine within 28 days prior to Day 1 of Cycle 1Xx_NEWLINE_xXPatients planning for a live vaccineXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXLive attenuated vaccine within 4 weeks of study drugXx_NEWLINE_xXHas received a live vaccine within 30 days prior to first dose.Xx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXReceived or will receive a live vaccine within 30 days prior to first dose of study drugXx_NEWLINE_xXReceived a live vaccine within 30 days prior to first dose of study drugXx_NEWLINE_xXReceipt of a live vaccine within 4 weeks prior to rituximab administrationXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live, attenuated vaccine will be required during the studyXx_NEWLINE_xXInfluenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist®) within 4 weeks prior to Cycle 1, Day 1 or at any time during the study.Xx_NEWLINE_xXReceipt of a live vaccine within 30 days of planned start of study therapy.Xx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live attenuated vaccine will be required during the study;\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXLive-virus vaccination within 30 days prior to day 1 of protocol therapyXx_NEWLINE_xXLive vaccine ? 6 weeks prior to start of conditioning regimenXx_NEWLINE_xXReceipt of a live attenuated vaccine within 4 weeks prior to study drugXx_NEWLINE_xXReceipt of a live vaccine within 30 days of the start of treatment; examples are measles, mumps, rubella, varicella, yellow fever, rabies, Bacillus Calmette–Guerin (BCG), oral polio vaccine, and oral typhoid vaccineXx_NEWLINE_xXSubjects vaccinated with a live (attenuated) vaccine (e.g., FluMist) or a killed (inactivated)/subunit vaccine (e.g., PNEUMOVAX, Fluzone) within 28 days or 14 days, respectively, of the first planned dose of ETBX vaccineXx_NEWLINE_xXAdministration of attenuated vaccine within 4 weeks before enrollmentXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior the first dose of durvalumabXx_NEWLINE_xXPatients must not have live vaccine therapies for prevention of infectious diseases within 28 days of first nivolumab doseXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumabXx_NEWLINE_xXVaccination with a live virus vaccine or live attenuated vaccine within 28 days prior to D1C1Xx_NEWLINE_xXReceipt of live attenuated vaccine within 30 days prior to the first dose of IPXx_NEWLINE_xXReceived a live vaccine within 30 days of the first dose of study medicationXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXVaccination with a live vaccine a minimum of 28 days prior to the start of treatmentXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before treatment start or anticipation that such a live attenuated vaccine will be required during the study; influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to treatment start or at any time during the studyXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXReceived a live vaccine within 30 days of planned start of study medicationXx_NEWLINE_xXReceipt of live, attenuated vaccine within 30 days prior to the first dose of MEDI4736Xx_NEWLINE_xXThe participant has received a live vaccine within 30 days prior to the first dose of trial treatment.Xx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXVaccination with a live vaccine < 28 days prior to the start of treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to trial registration.Xx_NEWLINE_xXLive vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXTreatment with live vaccine within 30 days prior to the first dose of study medication are not eligibleXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXReceived a live vaccine within 30 days of planned start of study medicationXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of study drugXx_NEWLINE_xXReceived a live virus vaccine within 30 days of planned start of study treatmentXx_NEWLINE_xXVaccination with a live vaccine a minimum of 30 days prior to study treatmentXx_NEWLINE_xXReceipt of live, attenuated vaccine within 30 days prior to the first dose of Investigational Product;Xx_NEWLINE_xXHas received a live vaccine within 30 days prior to the radiation therapyXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks prior to randomizationXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXReceived a live virus vaccine within 30 days of planned start of trial treatmentXx_NEWLINE_xXReceived live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXLive vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXVaccination with a live vaccine within 28 days of the initiation of treatmentXx_NEWLINE_xXReceipt of live, attenuated vaccine within 28 days prior to the first dose of investigational products )Xx_NEWLINE_xXReceipt of live, attenuated vaccine within 30 days prior to the first dose of MEDI4736Xx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1Xx_NEWLINE_xXVaccination with a live vaccine within 28 days prior to randomizationXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1 Exclusion Criteria Unique to Cobimetinib:Xx_NEWLINE_xXPatients who have received a live vaccine within 30 days prior to the first dose of trial treatment.Xx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXHas received live vaccine within 30 days of the planned start of study therapyXx_NEWLINE_xXNon-oncology vaccine therapies for prevention of infection disease (e.g. seasonal flu vaccine, human papilloma virus vaccine) within 4 weeks of study drug administration. Vaccination while on study is also prohibited except for administration of the inactivated influenza vaccine.Xx_NEWLINE_xXImmunization with any attenuated live vaccine within 1 week prior to registrationXx_NEWLINE_xXVaccination with a live vaccine within 28 days prior to randomizationXx_NEWLINE_xXUnwilling to avoid vaccinations with live vaccine and concomitant use of attenuated live vaccinesXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of study drugXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the studyXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of study treatmentXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 30 days before first dose of study treatment.Xx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab; inactivated vaccines, such as the injectable influenza vaccine, are permittedXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab (MEDI4736) or tremelimumabXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the studyXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of study treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days of the first dose of study treatment.Xx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumabXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumabXx_NEWLINE_xXReceived a live vaccine within 30 days of planned start of study treatmentXx_NEWLINE_xXVaccination with a live vaccine a minimum of 28 days prior to randomizationXx_NEWLINE_xXLive or attenuated vaccines (other than experimental cancer vaccine therapy) within 28 days prior to receiving the first dose of MEDI-551Xx_NEWLINE_xXLive vaccine within 30 days prior to registration.Xx_NEWLINE_xXHas received a live vaccine within 30 days prior to first dose of study therapyXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumabXx_NEWLINE_xXPatient who have received a live vaccine within 30 days prior to cycle 1 day 1Xx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the studyXx_NEWLINE_xXInfluenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to Cycle 1, Day 1 or at any time during the study.Xx_NEWLINE_xXHave received a live vaccine within 30 days before the first dose of study treatmentXx_NEWLINE_xXReceipt of a live vaccine within 30 days of receipt of study therapyXx_NEWLINE_xXParticipant has received a live vaccine within 2 weeks (less than 14 days) prior to C1D1Xx_NEWLINE_xXSubject has received a live vaccine within 4 weeks prior to C1D1Xx_NEWLINE_xXAny patient receiving a live vaccine must allow a 4-week interval before starting treatment on this studyXx_NEWLINE_xXVaccination with a live vaccine a minimum of 28 days prior to the start of treatmentXx_NEWLINE_xXLive attenuated vaccinations 14 days prior to treatmentXx_NEWLINE_xXVaccination with a live-virus vaccine up to 4 weeks prior to onset of study treatment.Xx_NEWLINE_xXReceipt of a live (attenuated) vaccine within 1 month prior to ScreeningXx_NEWLINE_xXAdministration of a live/attenuated vaccine within 4 weeks prior to the first dose of study treatment, within 5 months following the administration of the last dose of study drug, or anticipation that such a live/attenuated vaccine will be required during the studyXx_NEWLINE_xXAdministration of live, attenuated vaccine within 8 weeks before the start of treatment (day 0) and throughout the studyXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the studyXx_NEWLINE_xXHas received a live vaccine within 30 days of planned start of study therapy.Xx_NEWLINE_xXReceipt of a live virus vaccine within 28 days prior to Day 1 of Cycle 1Xx_NEWLINE_xXHas received a live vaccine within 30 days prior to the planned first dose of study therapy.Xx_NEWLINE_xXVaccination with a live vaccine a minimum of 4 weeks prior to study enrollmentXx_NEWLINE_xXAdministration of live, attenuated vaccine within 8 weeks before the start of treatment (day 0) and throughout the studyXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXReceived live, attenuated vaccine within 28 days prior to the first dose of mogamulizumab;Xx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXReceipt of a live vaccine within 30 days of receipt of study therapyXx_NEWLINE_xXNo receipt of a live vaccine within 4 weeks prior to registrationXx_NEWLINE_xXVaccination with a live vaccine a minimum of 28 days prior to the start of Cycle 1Xx_NEWLINE_xXParticipant has received a live vaccine within 4 weeks prior to screeningXx_NEWLINE_xXAny plan to receive a live attenuated vaccine during study treatmentXx_NEWLINE_xXPatient who received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXPatient who received a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the studyXx_NEWLINE_xXAny non-oncology live viral vaccine therapies used for the prevention of infectious diseases.Xx_NEWLINE_xXInfluenza vaccination with live attenuated vaccine in the 2 weeks prior to randomizationXx_NEWLINE_xXReceived live vaccine within 28 days prior to enrollmentXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the studyXx_NEWLINE_xXPrior treatment with a cancer vaccineXx_NEWLINE_xXReceived a live vaccine within 30 days prior to day 1Xx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumabXx_NEWLINE_xXImmunization with a live/attenuated vaccine within 28 days prior to conditioningXx_NEWLINE_xXReceipt of live vaccine within 4 weeks prior to study drug administrationXx_NEWLINE_xXHas received a live vaccine within 30 days prior to first doseXx_NEWLINE_xXHas received a live vaccine within 28 days of planned start of study therapyXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of study therapyXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab; for example, the intramuscular influenza vaccine can be administered but the intranasal vaccine is a live attenuated virus that cannot be givenXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks for first study treatmentXx_NEWLINE_xXReceipt of any live vaccine within 4 weeks prior to first dose of study treatment.Xx_NEWLINE_xXWomen who have received typhoid vaccine within three years or any other vaccine within three months will be excludedXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the studyXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of study treatmentXx_NEWLINE_xXImmunization with a live, attenuated vaccine within 4 weeks prior to study enrollmentXx_NEWLINE_xXReceipt of live (including attenuated) vaccines during the study, or anticipation of need for such a vaccine during the study.Xx_NEWLINE_xXVaccination with live attenuated vaccine within 28 days prior to day 1 of PROSTVAC-V/F administration or vaccination with a killed vaccine within 14 days prior to day 1 of PROSTVAC-V/FXx_NEWLINE_xXLive attenuated vaccine within 4 weeks prior to first day of study treatmentXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab; inactivated vaccines, such as the injectable influenza vaccine, are permittedXx_NEWLINE_xXPlanned administration during the study of a HZ or varicella vaccine (including an investigational or non-registered vaccine) other than the study vaccine.Xx_NEWLINE_xXAdministration or planned administration of a live vaccine in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine.Xx_NEWLINE_xXAdministration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine.Xx_NEWLINE_xXInclusion Criteria:\n\n        Study entry (enrollment) occurs at the Pre-vaccination visit.\n\n          -  Subjects who the investigator believes can and will comply with the requirements of\n             the protocol.\n\n          -  Written informed consent obtained from the subject.\n\n          -  A male or female aged 18 years or older at the time of study entry.\n\n          -  Has undergone or will undergo autologous HCT within 50-70 days prior to the first\n             vaccination with the study vaccine/placebo, and there are no plans for additional\n             HCTs.\n\n          -  Female subjects of non-childbearing potential may be enrolled in the study. For this\n             study population, non-childbearing potential is defined as current tubal ligation,\n             hysterectomy, ovariectomy or post-menopause.\n\n        OR Female subjects of childbearing potential may be enrolled in the study, if the subject\n        has practiced adequate contraception for 30 days prior to vaccination with the study\n        vaccine/placebo, and has a negative pregnancy test on the day of vaccination, and has\n        agreed to continue adequate contraception during the entire treatment period and for 12\n        months after completion of the vaccination series (i.e., until Month 13).\n\n        Exclusion Criteria:\n\n          -  Use of any investigational or non-registered product other than the study vaccine\n             within 30 days preceding the first dose of study vaccine/placebo, or planned use\n             during the study period. However, the investigational use of a registered or\n             non-registered product to treat the subject's underlying disease for which the HCT was\n             undertaken, or a complication of the underlying disease, is allowed.\n\n          -  Previous vaccination against HZ or varicella within the 12 months preceding the first\n             dose of study vaccine/placebo.\n\n          -  Planned administration during the study of a HZ vaccine other than the study vaccine.\n\n          -  Occurrence of a varicella or HZ episode by clinical history within the 12 months\n             preceding the first dose of study vaccine/placebo.\n\n          -  History of allergic disease or reactions likely to be exacerbated by any component of\n             the vaccine or study material and equipment.\n\n          -  Prophylactic antiviral therapy with activity against Varicella Zoster Virus (VZV)\n             expected to last more than 6 months after transplantation.\n\n          -  Administration and/or planned administration of a vaccine not foreseen by the study\n             protocol between HCT and 30 days after the last dose of study vaccine/placebo.\n             However, licensed non-replicating vaccines may be administered up to 8 days prior to\n             dose 1and/or 2, and/or at least 14 days after any dose of study vaccine/placebo.\n\n          -  HIV infection by clinical history.\n\n          -  Pregnant or lactating female.\n\n          -  Female planning to become pregnant or planning to discontinue contraceptive\n             precautions (if of childbearing potential) before Month 13 (i.e., one year after the\n             last dose of study vaccine/placebo).Xx_NEWLINE_xXA subject previously enrolled in study NCT00294047, who received the control vaccine, and who cannot receive the GSK580299 vaccine because the subject is above the age for which the vaccine is licensed.Xx_NEWLINE_xXUse of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.Xx_NEWLINE_xXPlanned administration/administration of a vaccine not foreseen by the study protocol within 30 days (i.e., Day 0-29) of each dose of vaccine, with the exception of administration of routine meningococcal, hepatitis B, hepatitis A, inactivated influenza, diphtheria/tetanus and/or diphtheria/tetanus-containing vaccine up to 8 days before each dose of study vaccine. Enrolment will be deferred until the subject is outside of specified window.Xx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXReceived a live vaccine within 30 days of planned PD-1 start date.Xx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of study treatment.Xx_NEWLINE_xXSubjects must not have received a live attenuated vaccine within 28 days before the first dose of investigational agent, and subjects, if enrolled, should not receive live vaccines during the study or for 180 days after the last dose of investigational agent.Xx_NEWLINE_xXReceipt of a live, attenuated vaccine within 4 weeks prior to initiation of study drug (cycle 1, day 1 [C1D1]) or anticipation that such a live, attenuated vaccine will be required during the studyXx_NEWLINE_xXLive vaccine ? 4 weeks prior to enrollmentXx_NEWLINE_xXReceipt of live attenuated vaccination within 30 days prior to the first vaccineXx_NEWLINE_xXMale subjects who are not employing an effective method of birth control from starting vaccine, including dosing interruptions through 90 days after receipt of the last vaccine; refrain from sperm cell donation while receiving vaccination and for at least 90 days after the last vaccineXx_NEWLINE_xXHas received a live-virus vaccine within 30 days prior to the first dose of study treatmentXx_NEWLINE_xXAdministration of a live, attenuated vaccine within 28 days before Day 1 or anticipation that such a live attenuated vaccine will be required during the studyXx_NEWLINE_xXReceived a live viral vaccine within 6 months prior to the first dose of study drug.Xx_NEWLINE_xXReceived live vaccine within 28 days prior to enrollment.Xx_NEWLINE_xXHas taken any live vaccinations within 30 days before study drug administration except for the influenza vaccine.Xx_NEWLINE_xXReceipt of a live vaccine within 30 days of planned start of study drug.Xx_NEWLINE_xXNon-oncology vaccine therapies for prevention of infectious diseases (example, human papillomavirus [HPV] vaccine) within 4 weeks of study drug administration. The inactivated seasonal influenza vaccine can be given to participants before treatment and while on therapy without restriction. Influenza vaccines containing live virus or other clinically indicated vaccinations for infectious diseases (example, pneumovax, varicella) may be permitted but must be discussed with the sponsor's medical monitor and may require a washout period before and after administration of vaccine.Xx_NEWLINE_xXHas received a live vaccine within 30 days prior to randomization.Xx_NEWLINE_xXAdministration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1Xx_NEWLINE_xXHave received a live vaccination within 30 days of study start.Xx_NEWLINE_xXReceived live vaccine within 28 days prior to enrollment.Xx_NEWLINE_xXReceipt of a live vaccine within 30 days of planned start of study therapyXx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXHas received a live vaccine within 30 days prior to first dose of study drug.Xx_NEWLINE_xXHas received a live vaccine within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xX